Skip to main content

Table 3 Salient Grade 3 or Worse Adverse Events Attributed to Neoadjuvant Study Treatment

From: Results of a planned interim toxicity analysis with trimodality therapy, including carboplatin AUC = 4, paclitaxel, 5-fluorouracil, amifostine, and radiation for locally advanced esophageal cancer: preliminary analyses and treatment recommendations from the North Central Cancer Treatment Group

ADVERSE EVENT ABSOLUTE INCIDENCE NUMBER OF PATIENTS WITH EVENT
death (paclitaxel reaction) 1 1
neutropenia 11 9
leukopenia 12 10
febrile neutropenia 5 5
hypotension 4 3
vomiting 4 3
nausea 2 2
dehydration 2 2
diarrhea 2 2
dysphagia 6 6
electrolyte abnormalities 6 4
dyspnea 1 1
pain (non-specific) 1 1
rash 1 1
mucositis 1 1
fatigue 2 2
syncope 1 1
hypersensitivity 1 1
neuropathy 1 1
infection 1 1
melena 1 1